We are live on ! Find out more
ZNTL icon

Zentalis Pharmaceuticals

106 hedge funds and large institutions have $1.3B invested in Zentalis Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 48 increasing their positions, 30 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

6,496% more call options, than puts

Call options by funds: $1.58M | Put options by funds: $24K

227% more capital inflows, than outflows

Capital inflows: $160M | Capital outflows: $48.8M

150% more funds holding in top 10

Funds holding in top 10: 2 → 5 (+3)

60% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 30

9.56% more ownership

Funds ownership: 103.19% → 112.74% (+9.6%)

12% less funds holding

Funds holding: 120 → 106 (-14)

75% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 20

Holders
106
Holders Change
-14
Holders Change %
-11.67%
% of All Funds
1.7%
Holding in Top 10
5
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+150%
% of All Funds
0.08%
New
5
Increased
48
Reduced
30
Closed
20
Calls
$1.58​M
Puts
$24​K
Net Calls
+$1.56​M
Net Calls Change
-⁠$2.23​M

ZNTL Hedge Fund Activity: Q4 2022 in Review

106 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q4 2022, worth a combined $1.3B — up 1.7% from $1.27B a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of ZNTL and 5 opened new positions — a net loss of 15 holders — while 30 trimmed existing stakes and 48 added.

The largest buyer was Capital International Investors, opening a new position worth an estimated $65.6M. The largest seller was Polar Capital Holdings, exiting entirely with an estimated $8.18M sold.

  • 106 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q4 2022, down from 120 in Q3 2022.
  • Funds reported $1.3B of Zentalis Pharmaceuticals stock for Q4 2022, up 1.7% quarter-over-quarter.
  • 5 funds opened new Zentalis Pharmaceuticals positions in Q4 2022 and 20 closed out, a net change of -15 holders.
  • The largest Zentalis Pharmaceuticals buyer in Q4 2022 was Capital International Investors, an estimated $65.6M added.
  • The largest Zentalis Pharmaceuticals seller in Q4 2022 was Polar Capital Holdings, an estimated $8.18M sold.

Based on aggregated 13F filings for Q4 2022.